Compare PBH & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | INSP |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.2B |
| IPO Year | 2004 | 2018 |
| Metric | PBH | INSP |
|---|---|---|
| Price | $61.40 | $58.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 16 |
| Target Price | $80.75 | ★ $101.07 |
| AVG Volume (30 Days) | 361.9K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.88 | ★ 179.43 |
| EPS | 2.78 | ★ 4.89 |
| Revenue | ★ $975,777,000.00 | $82,050,000.00 |
| Revenue This Year | N/A | $8.44 |
| Revenue Next Year | $2.15 | $8.60 |
| P/E Ratio | $22.30 | ★ $11.92 |
| Revenue Growth | 36.77 | ★ 62.18 |
| 52 Week Low | $57.25 | $53.11 |
| 52 Week High | $88.55 | $172.95 |
| Indicator | PBH | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 34.22 |
| Support Level | $60.75 | $55.34 |
| Resistance Level | $63.26 | $84.26 |
| Average True Range (ATR) | 1.83 | 4.28 |
| MACD | -0.97 | 0.53 |
| Stochastic Oscillator | 1.41 | 4.27 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.